AstraZeneca sees years of growth as drug sales turn corner

LONDON (Reuters) - Strong demand for AstraZeneca's new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement.Product sales in the three months rose 8 percent, or 9 percent in constant currencies, which is the benchmark AstraZeneca uses for measuring the return to growth that it has been promising for 2018.Shares in the group, which staved off a takeover bid from Pfizer four years ago,..